Edition:
United Kingdom

Celyad SA (CYAD.BR)

CYAD.BR on Brussels Stock Exchange

32.18EUR
18 Dec 2017
Change (% chg)

€-0.82 (-2.48%)
Prev Close
€33.00
Open
€33.01
Day's High
€34.03
Day's Low
€32.00
Volume
55,256
Avg. Vol
66,629
52-wk High
€56.48
52-wk Low
€17.24

Chart for

About

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company's product, C-Cure,... (more)

Overall

Beta: 1.65
Market Cap(Mil.): €493.66
Shares Outstanding(Mil.): 9.52
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Celyad ends Q3 with EUR 40 million in cash, confirms previous guidance

* CONFIRMS ITS PREVIOUS GUIDANCE THROUGH TO THE FIRST HALF 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

17 Nov 2017

BRIEF-Celyad reports first complete response in relapsed refractory AML patient in THINK trial ‍​

* REPORTS A FIRST COMPLETE RESPONSE IN A RELAPSED REFRACTORY AML PATIENT IN THE THINK TRIAL ‍​

03 Oct 2017

BRIEF-Celyad SA files for mixed shelf offering of up to $250 mln

* Celyad SA files for mixed shelf offering of up to $250 million - SEC filing ‍​ Source text: [http://bit.ly/2xBg9Sn] Further company coverage:

31 Aug 2017

BRIEF-Celyad H1 operating loss narrows to 13.7 million euros

* H1 OPERATING LOSS EUR 13.7 MILLION VERSUS LOSS OF EUR 17.2 MILLION YEAR AGO

29 Aug 2017

BRIEF-BioLife Solutions executes supply agreement with Celyad for CryoStor

* Biolife Solutions executes supply agreement with Celyad for CryoStor use in natural killer receptor based t-cell (nkr-t) platform targeting solid tumors and blood cancers

31 Jul 2017

BRIEF-Celyad announces initiation of the SHRINK trial

* SHRINK TRIAL IS THIRD CLINICAL TRIAL WITH ITS LEAD PRODUCT CANDIDATE CYAD-01 (CAR-T NKG2D), TARGETING METASTATIC COLORECTAL PATIENTS

20 Jul 2017

BRIEF-Celyad publishes additional pre-clinical data in support of THINK trial ‍​

* PUBLISHES ADDITIONAL PRE-CLINICAL DATA IN SUPPORT OF THINK TRIAL ‍​

21 Jun 2017

Earnings vs. Estimates